Trial Profile
Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 04 May 2016 Status changed from active, no longer recruiting to discontinued.
- 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 26 Jan 2015 Planned number of patients changed from 200 to 300 as reported by ClinicalTrials.gov record.